BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) reported that on August 8, 2026, its board compensation committee approved equity inducement grants of restricted stock units to 56 new employees, covering an aggregate of 66,705 shares of common stock. One-fourth of each grant will vest on August 16, 2027, with the remaining shares vesting in equal quarterly installments thereafter, subject to continued employment. The awards were granted as inducements to employment under Nasdaq Listing Rule 5635(c)(4) and pursuant to a company plan adopted in November 2019 and amended in February and December 2023.

News Explained

BridgeBio approved inducement restricted stock units covering 66,705 common shares for 56 new employees; because one-fourth vests on August 16, 2027 and the remainder quarterly, the grants create potential future equity dilution rather than an immediate full share issuance.

Market Context

BridgeBio's prior inducement-grant notice was followed by -3.27% over 24 hours, providing a company-...

Analysis

BridgeBio's prior inducement-grant notice was followed by -3.27% over 24 hours, providing a company-specific comparison. The active S-3ASR is a resale registration for 24,628,286 shares; the company receives no proceeds, while insider activity was net selling.

Key Figures

Announcement date: August 11, 2026 Grant approval date: August 8, 2026 Employees receiving grants: 56 employees +3 more

6 metrics

Announcement date August 11, 2026 News publication

Grant approval date August 8, 2026 Compensation committee approval

Employees receiving grants 56 employees New employees

Shares granted 66,705 shares Aggregate restricted stock units

Initial vesting date August 16, 2027 One-fourth of shares underlying each RSU

Subsequent vesting schedule One-twelfth of remaining shares Quarterly vesting after the initial vesting date

Historical Context

5 past events · Latest: Aug 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 03	Earnings scheduling	Neutral	-0.2%	Scheduled second-quarter 2026 results release; the 24-hour price reaction was -0.16%.
Jul 22	FDA filing acceptance	Positive	+0.3%	FDA accepted the encaleret NDA and assigned a May 8, 2027 PDUFA date.
Jul 10	Inducement equity grants	Neutral	-3.3%	Grants covered 83,283 shares for 37 new employees; the reaction was -3.27%.
Jul 02	Clinical analysis	Positive	+3.6%	Acoramidis analyses reported kidney-related effects and a 3.58% 24-hour price reaction.
Jul 01	Preferred equity financing	Positive	+0.1%	BridgeBio announced preferred equity financing of up to $1 billion.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Responses varied across the selected events, with positive developments generally producing positive reactions while the prior inducement-grant notice was followed by a negative reaction.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"approved equity grants to 56 new employees in restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 56 new employees in restricted stock units for an aggregate of 66,705 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com   
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

FAQ

What inducement grants did BridgeBio Pharma (BBIO) announce on August 11, 2026?

BridgeBio Pharma announced equity inducement grants of restricted stock units covering 66,705 shares of common stock to 56 new employees. According to the company, these awards were approved on August 8, 2026, as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).

How many BridgeBio Pharma (BBIO) employees are receiving inducement RSUs and how many shares are involved?

According to BridgeBio Pharma, 56 new employees are receiving inducement restricted stock units representing an aggregate of 66,705 shares of common stock. The grants were approved by the compensation committee of the board of directors on August 8, 2026, as employment inducements.

What is the vesting schedule for the new BridgeBio Pharma (BBIO) inducement RSU grants?

The RSU grants vest over time, starting with one-fourth of each award vesting on August 16, 2027. According to BridgeBio Pharma, the remaining shares vest in equal quarterly installments, subject to the employee’s continued employment with the company or its subsidiaries.

Why were BridgeBio Pharma (BBIO) inducement RSUs granted under Nasdaq Listing Rule 5635(c)(4)?

BridgeBio Pharma states the RSUs were granted as inducements material to the employees entering into employment, in accordance with Nasdaq Listing Rule 5635(c)(4). This rule allows equity awards outside shareholder-approved plans when used as a material employment inducement.

Which equity plan governs the August 2026 inducement grants announced by BridgeBio Pharma (BBIO)?

According to BridgeBio Pharma, the inducement RSUs were granted pursuant to the terms of a company equity plan. The plan was adopted by the board of directors in November 2019 and was amended and restated on February 10, 2023 and December 13, 2023.

How could the August 2026 inducement RSUs affect BridgeBio Pharma (BBIO) share count?

If fully vested and settled in shares, the inducement RSUs would result in issuance of up to 66,705 additional shares of common stock. According to BridgeBio Pharma, these awards are subject to vesting conditions tied to continued employment.